Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Cagrilintide?
Cagrilintide is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase III program in Obesity. According to Globaldata,...
Data Insights
Cagrilintide by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
Cagrilintide is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes. According to GlobalData,...